TD Cowen Maintains Buy on Biogen, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 74.6%

Neg 0% Neu 0% Pos 74.6%

TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $215 to $225.

Comments

No comments yet. Be the first!